CoCites: A citation-based method for searching scientific literature

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland, Randy D Gascoyne, Joseph M Connors. Blood 2007
Times Cited: 900

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong, Won Seog Kim, Antonio Pinto, Yuan-Kai Shi, Yoichi Tatsumi, Mikkel Z Oestergaard, Michael Wenger, Günter Fingerle-Rowson, Olivier Catalani, Tina Nielsen, Maurizio Martelli, Laurie H Sehn. J Clin Oncol 2017
Times Cited: 226

List of shared articles

Times cited

Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice.
Theresa Weber, Roland Schmitz. Curr Oncol Rep 2022

Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Yoshihito Uchino, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura. Expert Rev Anticancer Ther 2022

Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.
Alexey V Danilov, Massimo Magagnoli, Matthew J Matasar. Oncologist 2022

Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
Huang Huang, Asim Datye, Ming Fan, Andrea Knapp, Tina Nielsen, Alessia Bottos, Joseph N Paulson, Peter C Trask, Fabio Efficace. Cancer Med 2022

Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
Peng Zhao, Tao Yu, Zheng Pan. Ann Nucl Med 2021

Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
Kenneth Ofori, Govind Bhagat, Alex J Rai. Br J Clin Pharmacol 2021

BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Elizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, Guiyuan Lei, Richard Bourgon, An D Do, Eugene Kim, Liping Zhang, Pedro Farinha, Randy D Gascoyne,[...]. Clin Lymphoma Myeloma Leuk 2021

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Peiqi Zhao, Lei Zhu, Lanfang Li, Shiyong Zhou, Lihua Qiu, Zhengzi Qian, Wengui Xu, Huilai Zhang. Oncol Lett 2021

Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Gilles Salles. N Engl J Med 2021